A Well-Oiled Machine

If you’ve ever doubted that a 137-year-old blue-chip beast could still surprise Wall Street, take a look at Johnson & Johnson’s (JNJ) recent maneuvering. The company just turned in a surprisingly robust Q3 performance, with $24 billion in revenue and a raised full-year forecast.

But forget the top-line cheerleading. What I’m watching is where this growth is actually coming from. And here’s a hint: it’s not from Band-Aids or baby powder.

Let’s start with CARVYKTI, J&J’s CAR-T therapy for multiple myeloma that just clocked an 83.5% jump in global sales year-over-year.

In a world where most pharma companies would kill for mid-single-digit growth, J&J just hit warp speed in cell therapy. CARVYKTI raked in $524 million this quarter alone, up from $286 million a year ago.

What’s critical here is the signal. It confirms investor appetite for real innovation in oncology, not just incremental tweaks. CARVYKTI’s expansion into earlier lines of therapy is the kind of strategic repositioning that can turn a drug into a franchise.

Remember, Revlimid didn’t become a $10 billion blockbuster overnight either.

But the real masterstroke might be J&J’s January acquisition of Intra-Cellular Therapies. They paid $14.6 billion in cash for CAPLYTA, a drug that was already FDA-approved for schizophrenia and bipolar depression. That might have seemed steep – until the FDA handed over a golden ticket just days ago.

CAPLYTA is now approved as an adjunctive treatment for major depressive disorder (MDD), a behemoth of a market with over 22 million Americans in play.

The key isn’t just that CAPLYTA works, but that it’s that it works without the baggage. No significant weight gain, no cardiovascular risks, and in a 26-week study, 65% of patients achieved remission. In a sea of underwhelming SSRIs and SNRI fatigue, that’s big.

Now, CAPLYTA’s Q3 revenue came in at $240 million. Modest, sure, but that was before the MDD approval. Peak sales projections now stretch north of $5 billion.

That means J&J didn’t just acquire a drug; they acquired a psychiatric launchpad, with expansion potential into schizophrenia relapse prevention and a next-gen deuterated molecule (ITI-284) targeting generalized anxiety and Alzheimer’s psychosis. This is what we call a “pipeline-in-a-pill,” and J&J now owns the launch codes.

Meanwhile, DARZALEX FASPRO, the company’s subcutaneous version of daratumumab, is quietly becoming the backbone of their oncology portfolio. In Q3 alone, it generated $3.67 billion, up nearly 22%.

But what really made waves was its new FDA nod to treat high-risk smoldering multiple myeloma (HR-SMM). To date, HR-SMM patients had no real treatment options—just “active monitoring” and a prayer.

Now, thanks to the Phase 3 AQUILA study, J&J can offer them early intervention. 63% of treated patients hadn’t progressed to full-blown multiple myeloma after five years, versus just 41% with the standard watch-and-wait approach.

Behind the scenes, J&J’s neuroscience portfolio is also quietly humming. SPRAVATO, their esketamine nasal spray for treatment-resistant depression, posted a jaw-dropping 61.5% revenue surge to $459 million. It’s not making headlines, but it should.

Esketamine is one of the few fast-acting antidepressants with suicide prevention data behind it, and in a mental health crisis era, that’s not just good science, it’s good business.

Of course, no rose garden comes without a few thorns. STELARA and IMBRUVICA, once star performers, are showing signs of wear. Patent cliffs are creeping in, and biosimilar threats are circling. But the point is this: J&J’s pipeline is deeper than most realize. LAZCLUZE, ERLEADA, TREMFYA, and even the bispecific T-cell engagers like TALVEY and TECVAYLI—all posted double-digit gains last quarter.

At this point, J&J doesn’t need to prove it can be flashy. What it proves, quarter after quarter, is that focus, execution, and clinical depth still move the needle.

CAPLYTA’s approval wasn’t luck. Neither was DARZALEX’s expansion. These are the outcomes of a company that knows its business and plays to win without needing to shout about it. Not bad for a company that once sold baby oil.